General Information
Revision date
2020-02-27
Product name
Naproxen and Esomeprazole Magnesium Delayed-Release Tablets
CAS No.
217087-09-7
Manufacturer Name
Patheon Pharmaceuticals Inc.
Icons in SDS
Company Information
company name
Lupin Pharmaceuticals, Inc
Section 2
SECTION 2: Hazards identification
Fire and Explosion Expected to be non-combustible. Health Naproxen and esomeprazole magnesium delayed-release tablets are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen, esomeprazole magnesium, substituted benzimidazoles, or to any components of the drug product, including omeprazole. Hypersensitivity reactions to esomeprazole may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria. History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. In the setting of coronary artery bypass graft (CABG) surgery. Proton pump inhibitors (PPIs), including esomeprazole magnesium, are contraindicated in patients receiving rilpivirine-containing products.
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.
